Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab Combinations in Advanced Solid Tumors
NCT03589651Phase 1Completed
- Sponsor
- Incyte
- Start
- Aug 2018
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of retifanlimab in solid tumor (advanced stage), sponsored by Incyte. Primary endpoint: Number of treatment-emergent adverse events at 30 months. Started Aug 2018; status: completed.
02
Drugs
retifanlimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03589651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589651.